110 related articles for article (PubMed ID: 34158264)
1. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction.
Tsilimidos G; Horisberger A; Ribi C; Cairoli A; Stalder G
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e745-e747. PubMed ID: 34158264
[No Abstract] [Full Text] [Related]
2. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F
Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526
[No Abstract] [Full Text] [Related]
3. A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
Carella M; Stefoni V; Broccoli A; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e817-e819. PubMed ID: 34281758
[No Abstract] [Full Text] [Related]
4. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
T Low J; B Peters K
CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
[TBL] [Abstract][Full Text] [Related]
5. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Okahashi N; Uchihara M; Hoshino E
Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
[TBL] [Abstract][Full Text] [Related]
6. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Wang L; Li X; He YZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
[No Abstract] [Full Text] [Related]
7. Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib.
Kallam A; Hansen N; Bierman P
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e930-e933. PubMed ID: 32782203
[No Abstract] [Full Text] [Related]
8. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
[No Abstract] [Full Text] [Related]
9. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
[TBL] [Abstract][Full Text] [Related]
11. Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Tanigawa T; Sakurai M; Kato J; Mizuno K; Fujita S; Koda Y; Kikuchi T; Shimizu T; Okamoto S; Kataoka K
Ann Hematol; 2022 Mar; 101(3):723-724. PubMed ID: 34235557
[No Abstract] [Full Text] [Related]
12. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
[No Abstract] [Full Text] [Related]
13. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
George P; Brown A; Weinkove R
Pathology; 2020 Jun; 52(4):491-492. PubMed ID: 32349864
[No Abstract] [Full Text] [Related]
14. Immediate reaction to ibrutinib amenable to oral desensitization.
Phadke NA; Luk SO; Hochberg EP; Banerji A
J Oncol Pharm Pract; 2021 Oct; 27(7):1802-1805. PubMed ID: 33793357
[TBL] [Abstract][Full Text] [Related]
15. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Fowler NH; Nastoupil L; De Vos S; Knapp M; Flinn IW; Chen R; Advani RH; Bhatia S; Martin P; Mena R; Davis RE; Neelapu SS; Eckert K; Ping J; Co M; Beaupre DM; Neuenburg JK; Palomba ML
Br J Haematol; 2020 May; 189(4):650-660. PubMed ID: 32180219
[TBL] [Abstract][Full Text] [Related]
16. Complete Response of a Young Woman With MYD88
Pabon CM; Neff JL; Forns TE; Wang J
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904
[No Abstract] [Full Text] [Related]
17. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Cassin R; D Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Olivieri J; Cutrona G; Rossi D; Cuneo A; Di Raimondo F; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Am J Hematol; 2021 Aug; 96(8):E269-E272. PubMed ID: 33878220
[No Abstract] [Full Text] [Related]
18. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
19. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma.
Claves F; Siest R; Lefebvre C; Valmary-Degano S; Carras S
J Clin Immunol; 2021 Aug; 41(6):1380-1383. PubMed ID: 33871787
[No Abstract] [Full Text] [Related]
20. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]